Expert session, April 8th

 

Expert session, April 8th, Palais de l’Europe, Menton

Discussions between experts available for general audience

Presentations are available for viewing in PDF format but should not be used without authors’ permission

13.45 – Forewords (general): M. Meignan – A. Gallamini – C. Haioun 

14.00 – 16.00: PET Interpretation issues

Chairmen: S. Barrington, M. Meignan

1. Interpretation rules 1 year after Deauville, 3 different criteria (5PS, IHP, SUV), problems & reproducibility

M. Meignan, S. Bardet, S. Barrington, A. Biggi, O. Hoekstra, E. Itti, M. Juweid, S. Müller (round table): 50’

      • 5 point-scale (5PS) and Deauville criteria (M. Meignan): 10’ 
      • Limits of the IHP criteria (S. Bardet, M. Juweid): 10’ 
      • Size assessment of residual nodes (M. Meignan): 10’
      • Experience with 5PS in HL (S. Barrington, A. Biggi): 10’ ,
      • Experience with 5PS in NHL (E. Itti): 10’ 

2. Limited stage versus advanced stage HL : same criteria but different cutoff

      • Cutoff in limited and advanced stage HL (S. Barrington, M. Hutchings): 10’ 

3. Qualitative or quantitative: different or same rules for HL an DLBCL?

      • Qualitative or quantitative interpretation (M. Meignan): 5’ 
      • Quantification: cost or benefit (O. Hoekstra): 10’ 
      • Δ SUV in DLBCL (E. Itti, S. Müller): 10’ ,
      • Quantitative analysis: problems and reproducibility) (S.Müller): 5’ 
      • Contrast media and SUV measurement in lymphoma (P.Vera): 5’ 

4. Standardization: need for European guidelines, central data analysis/QA/review and site accreditation

      • GITIL plateform (S. Chauvie): 5’ 
      • EORTC platform (J. Flament): 5’ 
      • GELA platform (Meignan): 5’ 

16.00 – 16.20: Discussion (experts and attendees)

16.30 – 16.40: Coffee break

16.40 – 17.20: IVS problems

Chairmen: C. Thieblemont, J. Zijlstra

5. IVS problems in HL and NHL

      • IVS problems in ABVD-treated HL (A. Gallamini): 10’ 
      • IVS problems in DLBCL (C. Haioun, E. Itti): 10’ 
      • Interpretation in BEACOPP-treated HL (A. Avigdor): 5’ 
      • Dynamic PET (E. Dann): 5’ 

17.20 – 17.30: Discussion

17.30 – 18.00: Perspectives

Chairmen: O. Hoekstra, C. Haioun

6. Thymidine in lymphoma: imaging proliferation

      • 18F-thymidine in lymphoma (A. Buck): 30’ 

19.00: Welcome party, Villa Maria Serena

Invitation of the Experts by

Mr. Jean-Claude Guibal Member of Parliament, Mayor of Menton